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Background: Polycystic ovary syndrome (PCOS) has a risk for cardiovascular disease. Increased arterial stiffness has
been observed in women with PCOS. The purpose of the present study was to investigate whether the brachial-to-ankle
pulse wave velocity (baPWV) is a prognostic factor for ovulatory response to clomiphene citrate (CC) in women
with PCOS.
Methods: This study was a retrospective cohort study of 62 women with PCOS conducted from January 2009 to
December 2012 at the university hospital, Yamagata, Japan. We analyzed 62 infertile PCOS patients who received
CC. Ovulation was induced by 100 mg CC for 5 days. CC non-responder was defined as failure to ovulate for at
least 2 consecutive CC-treatment cycles. The endocrine, metabolic, and cardiovascular parameters between CC
responder (38 patients) and non-responder (24 patients) groups were analyzed.
Results: In univariate analysis, waist-to-hip ratio, level of free testosterone, percentages of patients with dyslipidemia,
impaired glucose tolerance, and diabetes mellitus, blood glucose and insulin levels at 60 min and 120 min, the area
under the curve of glucose and insulin after 75-g oral glucose intolerance test, and baPWV were significantly higher in
CC non-responders compared with responders. In multivariate logistic regression analysis, both waist-to-hip ratio
(odds ratio, 1.77; 95% confidence interval, 2.2–14.1; P = 0.04) and baPWV (odds ratio, 1.71; 95% confidence interval,
1.1–2.8; P = 0.03) were independent predictors of ovulation induction by CC in PCOS patients. The predictive values
of waist-to-hip ratio and baPWV for the CC resistance in PCOS patients were determined by the receiver operating
characteristic curves. The area under the curves for waist-to-hip ratio and baPWV were 0.76 and 0.77, respectively.
Setting the threshold at 0.83 for waist-to-hip ratio offered the best compromise between specificity (0.65) and sensitivity
(0.84), while the setting the threshold at 1,182 cm/s for baPWV offered the best compromise between specificity (0.80)
and sensitivity (0.71).
Conclusions: Both metabolic and cardiovascular parameters were predictive for CC resistance in PCOS patients. The
measurement of baPWV may be a useful tool to predict ovulation in PCOS patients who receive CC.
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Polycystic ovary syndrome (PCOS) is a common ovulatory
disorder in young women, which affects 5–10% of the
population and results in infertility due to anovulation
[1]. Clomiphene citrate (CC) is a first-line strategy to in-
duce ovulation in women with PCOS. Although CC will
induce ovulation in 60–80% of PCOS patients, the re-
mainder are CC resistant [2,3]. CC-resistant women are
recommended for other treatments, such as gonadotropin
treatment or laparoscopic ovarian drilling to induce ovula-
tion. Although gonadotropin therapy achieves higher ovu-
lation and pregnancy rates, the treatment is associated
with serious complications, such as ovarian hyperstimula-
tion syndrome and multiple pregnancies [4,5]. Laparoscopic
ovarian drilling is invasive and expensive [5,6].
Although the pathogenesis of PCOS is still unclear, the
role of insulin resistance in the pathophysiology of PCOS
has been established. Insulin resistance with compensatory
hyperinsulinemia is common in women with PCOS [7].
Hyperinsulinemia directly contributes to an increase in
androgen biosynthesis in the ovary [8] and a decrease in
the level of hepatic sex hormone-binding globulin, resulting
in an elevated free androgen level [9]. Hyperandrogenism
within an ovary is believed to harm follicle development
in PCOS. On the basis of these considerations, insulin-
sensitizing drugs, such as metformin, pioglitazone, and rosi-
glitazone, have been used alone or in combination with CC
in CC-resistant PCOS patients to induce ovulation [5].
The mechanisms of CC resistance in women with PCOS
also remain unknown. Levels of testosterone [10] and
blood glucose and blood glucose × immunoreactive in-
sulin (IRI) at 120 min after oral glucose tolerance test have
been reported as predictive markers in CC-resistant PCOS
[11]. Because PCOS is associated with risk for developing
type 2 diabetes mellitus [12], these reports support the
idea that metabolic disorders could be involved in the
mechanisms of CC-resistant PCOS.
Women with PCOS also are at risk for developing car-
diovascular disease [13-16]. Increased arterial stiffness
has been observed in women with PCOS compared to
controls with normal menstrual cycles and normal an-
drogen levels [17,18]. Brachial-to-ankle pulse wave vel-
ocity (baPWV) is a surrogate marker for arterial stiffness
[19]. However, no reports concerning the association of
cardiovascular parameters, such as baPWV, with ovula-
tory response to CC in women with PCOS have been
published. The purpose of the present study was to in-
vestigate whether the baPWV is a prognostic factor for
ovulatory response to CC in women with PCOS.
Methods
Subjects
This study was a retrospective cohort observational study.
A total of 62 infertile patients diagnosed with PCOS fromJanuary 2009 to December 2012 in our hospital were re-
cruited into the study. The ethics committee at Yamagata
University Faculty of Medicine approved the study proto-
col. We previously reported that this cohort of seven
women with PCOS who were CC-resistant successfully
ovulated by co-treatment with bezafibrate and CC [20]. A
written informed consent was obtained from all partici-
pants before entry into the study.
PCOS was diagnosed by the presence of oligomenorrhea
or amenorrhea, polycystic ovaries on ultrasonography, and
hyperandrogenemia or LH hypersecretion (elevated LH
level and LH/FSH ratio) according to the 2007 criteria of
the Japanese Society of Obstetrics and Gynecology (JSOG)
[21]. Pelvic transvaginal ultrasound was performed using a
5 to 7.5-MHz probe in oligo-/amenorrheic women at ran-
dom or days 3–5 after a spontaneous or a progestin-
induced withdrawal bleeding. In the JSOG PCOS diagnostic
criteria, a diagnosis of PCO was made if there were 10 or
more follicles of 2–9 mm in diameter [21]. Because the
prevalence of Japanese PCOS women with a sign of hyper-
androgenism is very low [22], the clinical hyperandrogen-
ism, such as hirsutism, is not included in the JSOG PCOS
diagnostic criteria. Hyperandrogenemia was defined as an
increase in the level of total testosterone, free testosterone
or androstenedione concentration in the JSOG PCOS
diagnostic criteria [21]. In the present study, we used
the concentration of free testosterone over 1.0 pg/ml as
hyperandrogenemia. The JSOG PCOS diagnostic cri-
teria includes the Rotterdam 2003 criteria for PCOS
[23]. Other etiologies such as congenital adrenal hyperpla-
sia, androgen secreting tumor, or Cushing’s syndrome
were excluded [21,23]. Inclusion criteria included normal
semen analysis according to World Health Organization
criteria and normal hysterosalpingography within the pre-
ceding 6 months. Exclusion criteria included the presence
of any infertility factors other than PCOS and the use of
any medications, such as insulin sensitizers, lipid-lowering
drugs, or anti-hypertensive drugs. Patients who were
already diagnosed with impaired glucose tolerance or
diabetes mellitus and smokers were also excluded from
the study.
All patients were received CC (Shionogi Co. Ltd., Tokyo
Japan) at 100 mg daily for 5 days from day 3–5 after a
spontaneous or a progestin-induced withdrawal bleeding
[20,24]. The patients were followed up with transvaginal
ultrasound to record follicular growth from day 10–12 of
the cycle. When a follicle of at least 18 mm was found,
5,000 IU of human chorionic gonadotropin (hCG, Mochida
Co. Ltd., Tokyo Japan) was intramuscularly injected [25].
Artificial insemination with the husband’s semen or nat-
ural intercourse was performed after the hCG injection.
Serum progesterone was measured 7 days after hCG ad-
ministration. Ovulation was determined as the vanishing
of a follicle on transvaginal ultrasound, a rise in basal body
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day 7 after hCG administration [20]. If no follicular
growth was observed at day 21 of the menstrual cycle,
we discontinued the measurement of follicle growth and
recorded no ovarian response to CC. CC response was
defined as confirmed ovulation in at least one cycle of
CC administration [11]. CC non-response was defined
as failure to demonstrate an ovarian response, and no
ovulation for at least two consecutive cycles [20,26].
Hormonal assays
In the first cycle of CC treatment, all hormone measure-
ments were performed on day 3–5 after a spontaneous
or a progestin-induced withdrawal bleeding. Hormone
concentrations were quantified using commercially avail-
able immunoassay kits. LH, FSH, PRL, and total testoster-
one were measured using an electrochemiluminescence
immunoassay (ECLusys reagent LH, FSH, prolactin, tes-
tosterone II kit; Roche Diagnostics, Inc., Tokyo, Japan).
Estradiol and progesterone levels were measured using
a chemiluminescence immunoassay (Architect estradiol
and progesterone kit; Abbott Japan, Inc., Tokyo, Japan).
Free testosterone and dehydroepiandrosterone sulfate
(DHEA-S) were measured by radioimmunoassay (DPC
Free Testosterone Kit and DHEA-S kit; Mitsubishi
Kagaku Iatron, Inc., Tokyo, Japan). Reliability criteria for
total testosterone and free testosterone assays were
established. The intra-assay coefficient of variation (CV)
was 4.7–5.3% and the detection limit of the assay was
10 ng/dl for total testosterone, whereas the intra-assay
CV was 5.7–7.4% and the detection limit of the assay
was 0.24 pg/ml for free testosterone. All samples were
assayed in duplicate.
Anthropometric measurements
In the first cycle of CC treatment, anthropometric mea-
surements were performed on day 3–5 after a spontan-
eous or a progestin-induced withdrawal bleeding. Body
height was measured to the nearest 0.5 cm using a stadi-
ometer, and body weight (in light clothing without shoes)
to the nearest 0.5 kg on a calibrated balance scale. Each
patient’s waist circumference was measured with a soft
tape midway between the lowest rib and the iliac crest in
the standing position. Hip circumference was measured at
the widest part of the gluteal region, and the waist-to-hip
ratio was calculated. Body mass index (BMI, kg/m2) was
calculated as weight in kilograms divided by the square of
height in meters. Obesity was defined as BMI ≥ 30 kg/m2.
Measurements of metabolic parameters
In the first cycle of CC treatment, a blood sample was
collected by venipuncture on day 3–5 after a spontan-
eous or a progestin-induced withdrawal bleeding. Serum
levels of triglycerides, low-density lipoprotein (LDL)cholesterol, high-density lipoprotein (HDL) cholesterol,
and total cholesterol were measured by an enzymatic
assay. The diagnostic criteria for dyslipidemia were LDL
cholesterol ≥ 140 mg/dl, HDL cholesterol < 40 mg/dl, or
triglycerides ≥ 150 mg/dl according to the Japan Athero-
sclerosis Society’s Guidelines for the Diagnosis and Pre-
vention of Atherosclerotic Cardiovascular Diseases in
Japanese [27].
Fasting plasma glucose (FPG) was measured by en-
zyme assay, and fasting IRI was measured by enzyme
immunoassay. Glucose tolerance was determined by a
75-g oral glucose tolerance test (75-g OGTT). The diag-
nostic criteria for diabetes mellitus were in accordance
with the Committee of the Japan Diabetes Society on the
Diagnostic Criteria of Diabetes Mellitus [28]. Impaired
glucose tolerance was defined as a 2-h postload plasma
glucose level ≥ 140 mg/dl in subjects not meeting the
criteria for diabetes mellitus [28]. The responses of glu-
cose and insulin to 75-g OGTT were analyzed by calcu-
lating the area under the curve (AUC) for glucose and
the AUC for insulin using a trapezoidal method. Insulin
resistance was determined by homeostasis model assess-
ment of insulin resistance (HOMA-IR) and quantitative
insulin-sensitivity check index (QUICKI). The HOMA-
IR was calculated using the formula FPG (mg/dl) × fast-
ing IRI (μU/ml)/405, while the QUICKI was calculated
as 1/(log fasting IRI [μU/ml] + log FPG [mg/dl]). Patients
with HOMA-IR > 2.0 were considered insulin resistant.
Fasting venous blood samples were taken on a random
day, between 8:30 and 10:30 AM after a 12-h overnight
fast, before initiation of ovulation induction with CC.
Measurements of cardiovascular parameters
In the first cycle of CC treatment, measurements of car-
diovascular parameters were performed on day 3–5 after
a spontaneous or a progestin-induced withdrawal bleed-
ing. Blood pressure was measured in the supine position
on the right arm after a 10-min rest; a standard sphyg-
momanometer of appropriate cuff size was used, and the
first and fifth phases were recorded. Values used in the
analysis are the average of 3 readings taken at 5-min in-
tervals. The diagnostic criteria for hypertension were
systolic blood pressure ≥ 140 mmHg or diastolic blood
pressure ≥ 90 mmHg based on the Japanese Society of
Hypertension Guidelines for the Management of Hyper-
tension [29]. Mean blood pressure, which indicates overall
peripheral resistance, was calculated as diastolic pressure
plus one-third of the pulse pressure. baPWV, which
indicates arterial stiffness, was measured using a volume-
plethysmographic apparatus (form ABI; Omron Colin,
Co., Ltd., Tokyo, Japan). The patient was examined in the
supine position after resting for at least 5 min, with elec-
trocardiogram electrodes placed on both wrists, a micro-
phone to detect heart sounds placed on the left edge of
Table 1 Clinical characteristics and endocrine parameters







Age (y) 30.5 ± 4.7 31.5 ± 3.7 0.38
BMI (kg/m2) 23.7 ± 5.6 25.7 ± 6.4 0.21
No. of patients
with < 18.5 BMI (%)
4 (11) 3 (13) 0.83
No. of patients with
18.5 ≤ BMI < 25 (%)
22 (58) 9 (38) 0.19
No. of patients with
25 ≤ BMI < 30 (%)
6 (16) 7 (29) 0.22
No. of patients
with ≥ 30 BMI (%)
6 (16) 5 (21) 0.74
Gravida* 0 (0–3) 1 (0–4) 0.26
Parity* 0 (0–1) 0 (0–1) 0.82
Waist (cm) 78.2 ± 12.4 84.0 ± 12.3 0.11
Hip (cm) 95.82 ± 9.1 96.9 ± 8.8 0.67
Waist-to-hip ratio 0.81 ± 0.06 0.88 ± 0.07 0.001
LH (mIU/ml) 10.7 ± 3.8 12.3 ± 7.3 0.25
FSH (mIU/ml) 7.0 ± 1.7 6.6 ± 1.1 0.32
LH/FSH 1.6 ± 0.6 1.8 ± 0.9 0.23
PRL (ng/ml) 12.1 ± 5.8 12.3 ± 7.3 0.92
E2 (pg/ml) 46.93 ± 20.6 50.2 ± 18.2 0.54
Testosterone (ng/ml) 78.5 ± 25.8 99.6 ± 33.9 0.11
Free testosterone (pg/ml) 0.80 ± 0.34 1.17 ± 0.69 0.006
DHEA-S (μg/dl) 2095 ± 683 2284 ± 814 0.50
CC: clomiphene citrate, BMI: body mass index, DHEA-S: dehydroepiandrosterone
sulfate.
*Median (range).
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ankles. The intra- and interassay CV were < 8% for
baPWV.
Statistical analysis
Because there were no studies in the literature on this
subject, we were unable to estimate pretest power.
Therefore, post hoc power analysis was performed by
G*Power Software (version 3.1.9.2). Data were presented
as mean ± SD if a normal distribution was expected;
otherwise, median and range were used. In univariate
analysis, differences in nominal variables between the
groups were compared with the χ2 test, unless the expected
frequency was < 5, in which case, the Fisher’s exact prob-
ability test was used. Differences in continuous variables
were analyzed by nonparametric Mann-Whitney U test.
The differences in continuous variables were compared
between groups using the Student’s t test. Multivariate
logistic regression analysis was applied to evaluate the
predictors for ovulatory response to CC in PCOS pa-
tients. P > 0.10 was used as a cutoff level to eliminate
non-significant predictors from the prognostic model.
The area under the receiver operating characteristic
curve was used to assess the discriminative ability of the
logistic models. Statistical analysis was performed with R
software (The R Foundation for Statistical Computing,
version 2.13.0). Significance was defined as P < 0.05.
Results
Thirty-eight PCOS patients (61%) were CC responders,
and 24 (39%) were non-responders. Table 1 summarizes
the clinical characteristics and endocrine parameters
of the CC responder and non-responder groups. Age,
BMI, the percentages of overweight (25 ≤ BMI < 30) and
obese (BMI ≥ 30) patients did not significantly differ be-
tween the groups. Waist-to-hip ratio was significantly
higher among CC non-responders than CC responders.
Although testosterone concentration did not differ be-
tween the groups, the level of free testosterone in CC
non-responders was significantly higher than that in
CC responders.
Table 2 summarizes the metabolic parameters in both
groups. The percentage of CC non-responders with dys-
lipidemia was significantly higher than that of CC re-
sponders. The lipid parameters of triglycerides, LDL
cholesterol, HDL cholesterol, and total cholesterol did
not significantly differ between the groups. The percentage
of patients with impaired glucose tolerance or diabetes mel-
litus was significantly higher among CC non-responders
than CC responders. In assessing the glycemic and insuline-
mic response to 75-g OGTT, the levels of fasting glucose
and IRI did not differ between groups, while the blood
glucose and IRI levels at 60 min and 120 min and theAUC of glucose and IRI were significantly higher among
CC non-responders than in CC responders. The values of
HOMA-IR and QUICKI, indicators for insulin resistance,
did not significantly differ between the groups.
Table 3 summarizes the cardiovascular parameters in
both groups. The levels of systolic, diastolic, and mean
blood pressure did not significantly differ, while baPWV
was significantly higher in the CC non-responder group
than in CC responders.
In multivariate logistic regression analysis, both waist-
to-hip ratio and baPWV were independent predictors
for ovulatory response to CC in the PCOS patients
(Table 4). Therefore, we validated the efficacy of meas-
urement of waist-to-hip ratio and baPWV for the predic-
tion of CC resistance in PCOS patients. Figure 1 shows
the receiver operating characteristic curves of waist-to-
hip ratio and baPWV for the prediction of CC resistance.
The AUCs for waist-to-hip ratio and baPWV were 0.76
and 0.77, respectively. Setting the threshold at 0.83 for
waist-to-hip ratio offered the best compromise between
Table 2 Metabolic parameters in CC responsive and





No. of patients with
dyslipidemia (%)
6 (16) 11 (38) 0.02
Triglycerides (mg/dl) 90.4 ± 44.9 117.1 ± 67.6 0.08
LDL cholesterol (mg/dl) 112.2 ± 44.6 116.0 ± 32.9 0.73
HDL cholesterol (mg/dl) 65.3 ± 13.5 60.1 ± 15.6 0.18
Total cholesterol (mg/dl) 192.0 ± 42.0 197.9 ± 31.6 0.57
No. of patients with
IGT or DM (%)
4 (11) 11 (46) 0.004
75-g OGTT
Plasma glucose (mg/dl)
Fasting 88.9 ± 8.4 89.6 ± 7.5 0.76
60 min 129.0 ± 36.3 159.9 ± 48.4 0.01
120 min 112.1 ± 21.6 129.7 ± 41.9 0.04
AUC glucose (mg×h/dl) 936.9 ± 192.6 1080.9 ± 267.3 0.03
IRI (μU/ml)
Fasting 9.6 ± 7.3 13.7 ± 9.7 0.09
60 min 67.1 ± 34.7 117.6 ± 90.0 0.007
120 min 61.2 ± 36.5 110.7 ± 107.5 0.02
AUC IRI (μU × h/ml) 473.3 ± 225.9 799.1 ± 609.1 0.009
HbA1c (%) 5.4 ± 0.4 5.6 ± 0.4 0.12
HOMA-IR 2.3 ± 1.9 3.4 ± 2.9 0.09
QUICKI 0.36 ± 0.04 0.34 ± 0.05 0.16
CC: clomiphene citrate, IGT: impaired glucose tolerance, DM: diabetes mellitus,
AUC: area under the curve, IRI: immunoreactive insulin, HbA1c: hemoglobin
A1c, HOMA-IR: homeostasis model assessment of insulin resistance,
QUICKI: quantitative insulin-sensitivity check index.
Table 4 Independent predictors for ovulatory response to
CC in patients with polycystic ovary syndrome
Independent variables Odds ratio
(95% confidence interval)
P value
Waist-to-hip ratio 1.77 (2.2–14.1) 0.04
baPWV 1.71 (1.1–2.8) 0.03
CC: clomiphene citrate, baPWV: brachial-to-ankle pulse wave velocity.
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the threshold at 1,182 cm/s for baPWV offered the best
compromise between specificity (0.80) and sensitivity
(0.71). For patients with waist-to-hip ratio ≥ 0.83, the posi-
tive and negative predictive values were 0.72 and 0.79,
respectively. For patients with baPWV ≥ 1,182 cm/s, the
positive and negative predictive values were 0.69 and
0.81, respectively.Table 3 Cardiovascular parameters in CC responsive and






No. of patients with
hypertension (%)
6 (16) 3 (13) 1.0
Systolic BP (mmHg) 118.5 ± 15.5 121.2 ± 16.1 0.54
Diastolic BP (mmHg) 69.3 ± 14.4 71.0 ± 11.8 0.64
Mean BP (mmHg) 85.7 ± 13.8 87.8 ± 12.9 0.58
baPWV (cm/s) 1113.9 ± 129.9 1249.2 ± 173.4 0.002
CC: clomiphene citrate, baPWV: brachial-to-ankle pulse wave velocity.Discussion
In the present study, we found that both metabolic and
cardiovascular parameters were predictive for CC resist-
ance in patients with PCOS. The measurement of waist-
to-hip ratio and baPWV may be useful tools to predict
the possibility for ovulation in PCOS patients who re-
ceive CC.
In the present study, waist-to-hip ratio was an inde-
pendent predictor for ovulatory response to CC in PCOS
patients. The waist-to-hip ratio correlates with visceral
adiposity in obese and non-obese women with PCOS
[30]. Douchi et al. reported that the ratio of trunk fat to
leg fat, which indicates visceral adiposity, is a good pre-
dictor for CC resistance in women with PCOS [31],
which is consistent with our findings. In their study, the
trunk-to-leg fat ratio was measured by dual-energy X-
ray absorptiometry. The measurement of waist-to-hip
ratio is an easy and more convenient method to predict
CC resistance in PCOS. Lord et al. reported that visceral
adiposity, but not body weight, BMI, or subcutaneous
adiposity, was strongly correlated with insulin resistance
in women with PCOS [30]. The increased visceral adiposityFigure 1 Receiver operating characteristic curve of waist-to-hip
ratio and brachial-to-ankle pulse wave velocity (baPWV) to
predict clomiphene citrate resistance in patients with polycystic
ovary syndrome.
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inflammatory action, and an increase in inflammatory cy-
tokines, such as tumor necrosis factor-α, interleukin-6,
and free fatty acids, which raise insulin resistance [32].
The insulin resistance of peripheral tissues is thought to
be an important etiological factor in PCOS [7]. These
results support the hypothesis that increased visceral
adiposity may be associated with CC resistance in PCOS
women. Furthermore, waist-to-hip ratio is a well-known
predictor for cardiovascular disease [33,34].
In the present study, baPWV was also an independent
predictor for ovulatory response to CC in patients with
PCOS. The baPWV is a surrogate marker for arterial
stiffness [19] and a strong independent predictor of car-
diovascular mortality in the patients with hypertension,
end-stage renal disease, and diabetes [35-37]. An associ-
ation between PCOS and arterial stiffness has been sug-
gested [17,38-40]. Kelly et al. first reported that the
brachial artery, but not aortic artery, PWV is signifi-
cantly higher in reproductive-aged women with PCOS
than in control women with regular menstrual cycles
and normal androgen levels [17]. Meyer et al. also re-
ported that central PWV in reproductive-aged women
with PCOS is significantly higher than that in control
women with regular menstrual cycles and normal an-
drogen levels [39]. Moreover, Sasaki et al. reported that
baPWV in reproductive-aged women with PCOS is
significantly higher than that in control women with
regular menstrual cycles and morphologically normal
ovaries [18].
PWV is known to increase with age and hypertension
in the general population [41]. Furthermore, several studies
have reported that PWV increases in diabetic, dyslipidemia,
and metabolic syndrome patients with insulin resistance
[42,43]. Both total cholesterol and HOMA-IR, an indicator
for insulin resistance, have been reported to correlate with
PWV in women with PCOS [39]. Dyslipidemia is a well-
known primary risk factor for the development of athero-
sclerosis and is very common in women with PCOS [44].
Therefore, dyslipidemia observed in reproductive-aged
women with PCOS may influence early alteration of arterial
structure, which leads to arterial stiffness.
No evidence of an association between PWV and CC
resistance in women with PCOS has been previously re-
ported. The precise mechanism for the increase in baPWV
among CC non-responders compared to CC responders
remains unclear. In the present study, although surrogate
markers for insulin resistance, HOMA-IR and QUICKI,
did not significantly differ between CC responders and
non-responders, the percentage of patients with dyslipid-
emia and impaired glucose tolerance or diabetes mellitus
in the CC non-responder group was higher compared to
CC responders. Because PWV increases in patients with
dyslipidemia and diabetes mellitus [43,45], these factorsmay be one of the causes for the increase in baPWV
among CC non-responders.
In the present study, free, but not total, testosterone
level was also significantly higher in the CC non-responder
group compared to CC responders. The free androgen
index (FAI), which is obtained as the quotient 100 ×
total testosterone/SHBG, has been reported as higher in
CC-resistant PCOS patients than in CC responders [46].
Moreover, Imani et al. reported that BMI, FAI, men-
strual cycle history, and ovarian volume are useful predic-
tors for CC resistance in infertile patients with World
Health Organization group-II ovulatory disorders including
PCOS [47]. These results indicate that hyperandrogenism,
which may impair ovarian follicle development, may be in-
volved in CC resistance in PCOS patients. In reproductive-
aged women without PCOS, SHBG levels, but not total or
free testosterone levels, were inversely associated with
subclinical cardiovascular disease assessed by coronary ar-
tery calcified plaques and carotid artery intima-media
thickness [48]. Creatsa et al. recently reported that higher
serum testosterone and FAI are associated with subclinical
atherosclerosis, while serum DHEA-S exhibits a negative
association with arterial stiffness in healthy recently meno-
pausal women [49]. These reports suggest that hyperan-
drogenism may be a link to the increased arterial stiffness
observed in CC non-responsive PCOS patients.
In the present study, we could not explore the possible
mechanisms involved in the increase in baPWV in CC-
resistant PCOS patients. Further investigations are needed
to demonstrate to link to the increase in arterial stiffness
in CC-resistant PCOS. Because women with PCOS have
multiple risk factors for cardiovascular disease (CVD)
[14-16], such as impaired glucose tolerance, dyslipidemia,
insulin resistance, and metabolic syndrome, the Androgen
Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
published a consensus statement regarding assessment of
CVD risk and CVD in women with PCOS [13].
Our study has certain limitations that should be noted.
First, as PCOS was diagnosed according to the 2007 criteria
of the JSOG [21], whose criteria matched the Rotterdam
2003 criteria [23], our findings might differ from other
PCOS cohorts diagnosed by different criteria, such as
National Institutes of Health 1990 and AE-PCOS. Be-
cause the prevalence of Japanese PCOS women with a
sign of hyperandrogenism is very low compared to Cau-
casian women [22], the results of this study may not be
extrapolated to other populations. Second, definitions
vary the dose required to define CC-resistance ranging
from 100 mg to 250 mg of CC [20,26,46,50,51]. In the
present study, we defined CC non-responder as failure
to ovulate with 100 mg of CC for at least 2 consecutive
CC-treatment cycles. The CC non-responder in our study
may ovulate in response to 150 mg of CC administration.
However, the doses in excess of 100 mg per day are not
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of Japan as well as Food and Drug Administration of
United States. Therefore, we could not prescribe more
than 100 mg per day of CC in this study. Lastly, because
of small sample size and retrospective study design, our
findings should be interpreted with caution and confirmed
by prospective study.
We performed a post hoc power analysis for the
waist-to-hip ratio, baPWV, blood glucose and IRI levels
at 60 min, and AUC of glucose and IRI with a two-sided
level of significance of 0.05 and found a power of 0.98,
0.91, 0.84, 0.79, 0.64, and 0.76, respectively. After eliminat-
ing confounding factors, the both waist-to-hip ratio and
baPWV were independent prognostic factors for ovulatory
response to CC in patients with PCOS in multivariate ana-
lysis. Moreover, the measurement of waist-to-hip ratio
and baPWV is quick and non-invasive to perform in com-
parison with blood sampling. Based on these results, both
waist-to-hip ratio and baPWV might be candidates for
prognostic factor for CC-resistant PCOS women.
In summary, the present study demonstrated that both
metabolic and cardiovascular parameters were predictive
for CC resistance in PCOS patients. The measurement
of waist-to-hip ratio and baPWV may be useful tools to
predict the possibility for ovulation in PCOS patients
who receive CC. This study provides the first evidence
of an association between arterial stiffness and CC re-
sistance in patients with PCOS. A prospective study
should be performed in order to access the clinical impact
of measurement of baPWV for predicting CC-resistant
PCOS women.
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